The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2024 | How might linvoseltamab fit into the myeloma treatment armamentarium?
Mansi Shah, MD, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, comments on the unique features of linvoseltamab as a treatment for relapsed/refractory (R/R) multiple myeloma. Dr Shah refers to the LINKER-MM1 study (NCT03761108), comparing the dosing and safety of linvoseltamab with other BCMA-directed antibodies, and shares her thoughts on how this agent may impact the treatment landscape. Dr Shah This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
